{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:14:45Z","timestamp":1768007685434,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ecl.2011.01.008","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T12:15:27Z","timestamp":1305202527000},"page":"419-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Blood Pressure Effects of the Oral Contraceptive and Postmenopausal Hormone Therapies"],"prefix":"10.1016","volume":"40","author":[{"given":"Angela","family":"Boldo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ecl.2011.01.008_bib1","first-page":"1","article-title":"Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth","author":"Chandra","year":"2005","journal-title":"Vital Health Stat 23"},{"key":"10.1016\/j.ecl.2011.01.008_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacc.2008.09.042","article-title":"Contraceptive hormone use and cardiovascular disease","volume":"53","author":"Shufelt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2011.01.008_bib3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1471-0528.1984.tb04747.x","article-title":"A\u00a0prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen","volume":"91","author":"Wilson","year":"1984","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ecl.2011.01.008_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00004872-199715100-00003","article-title":"Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994","volume":"15","author":"Dong","year":"1997","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ecl.2011.01.008_bib5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen","volume":"2","author":"Meade","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.01.008_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0010-7824(93)90034-5","article-title":"Effect of four combined oral contraceptives on blood pressure in the pill-free interval","volume":"47","author":"Nichols","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.CIR.94.3.483","article-title":"Prospective study of oral contraceptives and hypertension among women in the United States","volume":"94","author":"Chasan-Taber","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2011.01.008_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0895-7061(95)96212-3","article-title":"Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study","volume":"8","author":"Narkiewicz","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ecl.2011.01.008_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0010-7824(02)00429-8","article-title":"Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women","volume":"67","author":"Lubianca","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.jhh.1001841","article-title":"Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension","volume":"19","author":"Lubianca","year":"2005","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ecl.2011.01.008_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0020-7292(97)00239-7","article-title":"Low-dose oral contraceptives and 24-hour ambulatory blood pressure","volume":"59","author":"Cardoso","year":"1997","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ecl.2011.01.008_bib12","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.01.008_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00004872-199204000-00007","article-title":"Regulation of angiotensinogen gene expression by estrogen","volume":"10","author":"Gordon","year":"1992","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ecl.2011.01.008_bib14","doi-asserted-by":"crossref","first-page":"R807","DOI":"10.1152\/ajpregu.2001.280.3.R807","article-title":"Effect of oral contraceptives on the renin angiotensin system and renal function","volume":"280","author":"Kang","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ecl.2011.01.008_bib15","doi-asserted-by":"crossref","first-page":"F1539","DOI":"10.1152\/ajprenal.00351.2007","article-title":"The effect of oral contraceptives on the nitric oxide system and renal function","volume":"293","author":"Cherney","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ecl.2011.01.008_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000299563","article-title":"Effects of angiotensin II analog on blood pressure, renin and aldosterone in women on oral contraceptives and toxemia","volume":"12","author":"Saruta","year":"1981","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ecl.2011.01.008_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone, a progestogen with antimineralocorticoid properties: a short review","volume":"217","author":"Oelkers","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ecl.2011.01.008_bib18","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.HYP.0000242482.57186.e8","article-title":"Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats","volume":"48","author":"Arias-Loza","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.008_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/bmj.285.6339.403","article-title":"Blood pressure and contraceptive use","volume":"285","author":"Khaw","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.ecl.2011.01.008_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/01.HYP.33.1.90","article-title":"Renal characteristics and effect of angiotensin suppression in oral contraceptive users","volume":"33","author":"Ribstein","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.008_bib21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0895-7061(02)02980-1","article-title":"Additive effect of drospirenone\/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril","volume":"15","author":"Preston","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ecl.2011.01.008_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/01.gme.0000243572.63322.f7","article-title":"Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide","volume":"14","author":"Preston","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2011.01.008_bib23","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","article-title":"The protective effects of estrogen on the cardiovascular system","volume":"340","author":"Mendelsohn","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.008_bib24","first-page":"381","article-title":"Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys","volume":"99","author":"Kaplan","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2011.01.008_bib25","first-page":"250","article-title":"Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys","volume":"96","author":"Adams","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2011.01.008_bib26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM198811173192004","article-title":"A\u00a0prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases","volume":"319","author":"Stampfer","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.008_bib27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bmj.318.7198.1579","article-title":"Oral contraceptives and myocardial infarction: results of the MICA case-control study","volume":"318","author":"Dunn","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2011.01.008_bib28","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/01.CIR.98.11.1058","article-title":"Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies","volume":"98","author":"Sidney","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2011.01.008_bib29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa003216","article-title":"Oral contraceptives and the risk of myocardial infarction","volume":"345","author":"Tanis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.008_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2004.02.010","article-title":"Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives","volume":"70","author":"Sidney","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ecl.2011.01.008_bib32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.01.008_bib33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0010-7824(95)00271-5","article-title":"A\u00a0comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol","volume":"53","author":"Winkler","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0010-7824(01)00316-X","article-title":"An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables","volume":"65","author":"Endrikat","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.contraception.2004.08.017","article-title":"A\u00a01-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel","volume":"71","author":"Skouby","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2004.12.005","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism","volume":"71","author":"Klipping","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0010-7824(01)00269-4","article-title":"The effects of two progestogen-only pills containing either desogestrel (75 microg\/day) or levonorgestrel (30 microg\/day) on lipid metabolism","volume":"64","author":"Barkfeldt","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.ecl.2011.01.008_bib38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.008_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0037-1614089","article-title":"Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women","volume":"84","author":"Bar","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ecl.2011.01.008_bib40","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.ATV.18.6.961","article-title":"Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis","volume":"18","author":"Nakano","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2011.01.008_bib41","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/ATVBAHA.108.178004","article-title":"Certain progestins prevent the enhancing effect of 17beta-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells","volume":"29","author":"Zerr-Fouineau","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2011.01.008_bib42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00001721-200207000-00009","article-title":"Alterations in platelet function during the ovarian cycle","volume":"13","author":"Feuring","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.ecl.2011.01.008_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/09537100500227021","article-title":"The formation of platelet-leukocyte aggregates varies during the menstrual cycle","volume":"17","author":"Rosin","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.ecl.2011.01.008_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/09537100600936224","article-title":"Effect of oral contraceptives and ovarian cycle on platelet function","volume":"18","author":"Roell","year":"2007","journal-title":"Platelets"},{"key":"10.1016\/j.ecl.2011.01.008_bib45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0008-6363(01)00410-2","article-title":"Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca(2+) influx and raising cyclic adenosine monophosphate","volume":"53","author":"Nakano","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ecl.2011.01.008_bib46","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/AOG.0b013e3181d41191","article-title":"Role of hormone therapy in the management of menopause","volume":"115","author":"Shifren","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2011.01.008_bib47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.01.008_bib48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.01.008_bib49","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"4","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ecl.2011.01.008_bib50","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.1980.03310130021021","article-title":"Oral medroxyprogesterone in the treatment of postmenopausal symptoms","volume":"244","author":"Schiff","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.01.008_bib51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/01.HYP.25.3.305","article-title":"Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991","volume":"25","author":"Burt","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.008_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.jhh.1000476","article-title":"Conventional and ambulatory blood pressure and menopause in a prospective population study","volume":"11","author":"Staessen","year":"1997","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ecl.2011.01.008_bib53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000092984","article-title":"Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II","volume":"26","author":"Hernandez Schulman","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ecl.2011.01.008_bib54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200724060-00002","article-title":"Drospirenone, a new progestogen, for postmenopausal women with hypertension","volume":"24","author":"Mallareddy","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ecl.2011.01.008_bib55","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1161\/01.HYP.0000124670.03674.15","article-title":"Novel mechanisms responsible for postmenopausal hypertension","volume":"43","author":"Reckelhoff","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.008_bib56","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0015-0282(02)03078-9","article-title":"A\u00a0cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women","volume":"77","author":"Prelevic","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ecl.2011.01.008_bib57","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.01.008_bib58","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension","volume":"112","author":"White","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2011.01.008_bib59","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","article-title":"Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension","volume":"48","author":"White","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.008_bib60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.008_bib61","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/09513590600850300","article-title":"Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women","volume":"22","author":"Morgante","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ecl.2011.01.008_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1536\/ihj.51.60","article-title":"Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women","volume":"51","author":"Sumino","year":"2010","journal-title":"Int Heart J"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:30Z","timestamp":1760175330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852911000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0889852911000090"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2011.01.008","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood Pressure Effects of the Oral Contraceptive and Postmenopausal Hormone Therapies","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2011.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}